EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:NMTR

9 Meters Biopharma - NMTR Price Target & Analyst Ratings

$1.71
+0.01 (+0.59%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.65
$1.87
50-Day Range
$1.70
$4.70
52-Week Range
$1.65
$21.20
Volume
265,828 shs
Average Volume
118,808 shs
Market Capitalization
$22.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

9 Meters Biopharma Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$58.33
3,311.31% Upside
High Prediction$100.00
Average Prediction$58.33
Low Prediction$35.00
TypeCurrent
11/29/21 to 11/29/22
1 Month Ago
10/30/21 to 10/30/22
3 Months Ago
8/31/21 to 8/31/22
1 Year Ago
11/29/20 to 11/29/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$58.33$66.67$50.00$100.00
Predicted Upside3,311.31% Upside1,113.15% Upside762.07% Upside314.51% Upside
Get 9 Meters Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.


NMTR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NMTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

9 Meters Biopharma Stock vs. The Competition

Type9 Meters BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside3,341.49% Upside745.35% Upside14.46% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
36
78.26%
Underperform Votes
10
21.74%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.19%
Avg. Underperform Votes
398
31.81%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/10/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$57.00 ➝ $35.00+1,641.29%
10/25/2022Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
9/27/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$80.00 ➝ $100.00+1,946.66%
7/1/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
6/22/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$100.00 ➝ $40.00+589.65%
6/4/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
3/25/2021Brookline Capital Acquisition
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$120.00+324.03%
1/5/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
9/21/2020HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
6/30/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$100.00+791.74%
(Data available from 11/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NMTR Price Target - Frequently Asked Questions

What is 9 Meters Biopharma's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for 9 Meters Biopharma stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for NMTR. The average twelve-month price prediction for 9 Meters Biopharma is $58.33 with a high price target of $100.00 and a low price target of $35.00. Learn more on NMTR's analyst rating history.

Do Wall Street analysts like 9 Meters Biopharma more than its competitors?

Analysts like 9 Meters Biopharma more than other Medical companies. The consensus rating for 9 Meters Biopharma is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how NMTR compares to other companies.

Do MarketBeat users like 9 Meters Biopharma more than its competitors?

MarketBeat users like 9 Meters Biopharma more than other Medical companies. 78.26% of MarketBeat users gave 9 Meters Biopharma an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Does 9 Meters Biopharma's stock price have much upside?

According to analysts, 9 Meters Biopharma's stock has a predicted upside of 1,278.39% based on their 12-month price targets.

What analysts cover 9 Meters Biopharma?

9 Meters Biopharma has been rated by BMO Capital Markets, Brookline Capital Management, and Oppenheimer in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:NMTR) was last updated on 11/29/2022 by MarketBeat.com Staff